Drug development firm Merrion Pharmaceuticals has appointed Jonathan O'Connell as its new chief executive officer. He replaces John Lynch.
Mr O'Connell has been the company's chief financial officer since November 2005 and will also continue to fulfil this role as CEO.
'Jonathan O'Connell is an outstanding choice for CEO and has the ideal credentials to lead Merrion forward,' said the company's chairman Paddy O'Sullivan.
In February, the company reported a net loss of €2.5m for last year, compared with a loss of €1.6m a year earlier.
